PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 1,378 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels sold 1,378 shares of PTC Therapeutics stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $69,037.80. Following the transaction, the chief executive officer now directly owns 85,427 shares of the company’s stock, valued at $4,279,892.70. This represents a 1.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Eric Pauwels also recently made the following trade(s):

• On Tuesday, January 7th, Eric Pauwels sold 1,599 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $72,498.66.

PTC Therapeutics Price Performance

PTCT opened at $50.69 on Friday. The company’s 50-day moving average is $46.67 and its 200 day moving average is $41.49. PTC Therapeutics, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $54.16.

Analyst Ratings Changes

PTCT has been the subject of a number of research reports. Royal Bank of Canada raised their price target on shares of PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Tuesday. JPMorgan Chase & Co. raised their price target on shares of PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Barclays raised their price target on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 3rd. Cantor Fitzgerald raised their price target on shares of PTC Therapeutics from $76.00 to $113.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, UBS Group raised their price target on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $58.85.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PTCT. CWM LLC lifted its position in shares of PTC Therapeutics by 354.7% during the third quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,096 shares in the last quarter. Creative Planning raised its position in PTC Therapeutics by 8.1% in the third quarter. Creative Planning now owns 10,944 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 816 shares during the period. Assenagon Asset Management S.A. raised its position in PTC Therapeutics by 32.1% in the third quarter. Assenagon Asset Management S.A. now owns 492,464 shares of the biopharmaceutical company’s stock worth $18,270,000 after acquiring an additional 119,637 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in PTC Therapeutics by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 492 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in PTC Therapeutics by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,795 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 5,783 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.